Structural analysis of human glycoprotein butyrylcholinesterase using atomistic molecular dynamics: The importance of glycosylation site ASN241 by Bernardi, Austen et al.
RESEARCH ARTICLE
Structural analysis of human glycoprotein
butyrylcholinesterase using atomistic
molecular dynamics: The importance of
glycosylation site ASN241
Austen Bernardi1, Karl N. Kirschner2, Roland Faller1*
1 Department of Chemical Engineering, University of California–Davis, Davis, California, United States of
America, 2 Bonn–Rhein–Sieg University of Applied Sciences, Sankt Augustin, Germany
* rfaller@ucdavis.edu
Abstract
Human butyrylcholinesterase (BChE) is a glycoprotein capable of bioscavenging toxic com-
pounds such as organophosphorus (OP) nerve agents. For commercial production of
BChE, it is practical to synthesize BChE in non–human expression systems, such as plants
or animals. However, the glycosylation profile in these systems is significantly different from
the human glycosylation profile, which could result in changes in BChE’s structure and func-
tion. From our investigation, we found that the glycan attached to ASN241 is both structurally
and functionally important due to its close proximity to the BChE tetramerization domain and
the active site gorge. To investigate the effects of populating glycosylation site ASN241,
monomeric human BChE glycoforms were simulated with and without site ASN241 glycosy-
lated. Our simulations indicate that the structure and function of human BChE are signifi-
cantly affected by the absence of glycan 241.
Introduction
Butyrylcholinesterase (BChE) is a prophylactic therapeutic glycoprotein for organophosphorus
(OP) nerve agents [1]. OP nerve agents are toxic because they inhibit acetylcholinesterase
(AChE) [2], the hydrolyzing enzyme of neurotransmitter acetylcholine [3]. Some examples of
OP nerve agents include sarin, soman and tabun. BChE must be administered within two min-
utes of an OP exposure in humans, which inactivates the OP before local AChE is affected [4].
For a comprehensive review of OP nerve agents and their treatment, the reader is referred to
reference [5].
BChE naturally exists in humans and animals in monomeric, dimeric and tetrameric
forms, where each monomer acts as a stoichiometric scavenger of an OP nerve agent. These
oligomeric forms of BChE may be in either soluble, globular forms or anchored to a mem-
brane [6]. Monomeric BChE contains 574 amino acids with nine asparagine (N)±linked gly-
cans at residue indices 17, 57, 106, 241, 256, 341, 455, 481 and 486 [7]. The BChE N±
glycosylation sites follow the standard triplet motif: asparagine±X±threonine/serine, where X
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is any amino acid except proline [8]. N±glycosylation is a heterogeneous process that can affect
pharmacokinetic stability, immunocompatibility, reactivity, and thermal and kinetic stability
[9]. Glycans influence these factors through two motifs: direct interaction with their covalently
linked protein, or through external interactions with other molecules.
Structurally, BChE contains two distinct domains: the core domain (amino acids 1±529),
and the tetramerization domain (amino acids 530±574). The core domain is the stable folded
portion of monomeric BChE, and houses a single active gorge that contains the catalytic
SER198 residue at its base. BChE activity is irreversibly inhibited by OP nerve agents through
covalent modification of SER198. This reaction simultaneously deactivates BChE and destroys
the OP nerve agent, explaining BChE's bioscavenging ability [10]. However, there is evidence
that OP nerve agents are capable of covalently binding protein residues other than serine, such
as tyrosine and lysine [11]. The tetramerization domain is the flexible portion of BChE, and
participates in complexation of the BChE tetramer about a central polyproline helix.
The nine N±glycosylation sites of BChE are spread evenly across the core domain, with the
exception of the surfaces that contact other monomers in the tetramer. Of particular interest is
glycan 241, which, through the simulation presented herein, was found to interact with both
the tetramerization domain and the surface residues of the active site gorge. No other glycans
directly interact with the gorge, and the only other glycan to interact with the tetramerization
domain is glycan 256. Therefore, glycan 241 is likely the most relevant glycan when consider-
ing the functional performance of BChE. In this work we study the effects that glycan 241 has
on the structure and dynamics of monomeric human BChE using atomistic molecular dynam-
ics (MD). From the results, we hypothesize that the glycosylation state has a direct impact on
BChE's bioscavenger function. Atomistic MD enables the determination of time±ordered
atomic trajectories for timescales on the order of picoseconds to a microsecond and lengths-
cales on the order of nanometers [12], and is a powerful tool for investigating condensed mat-
ter systems in high detail. There have been quite a number of works on the simulation of
human BChE, ranging from mutation studies [13] to BChE±cocaine binding simulations [14]
to BChE tetramer model building [15]. However, this study is unique in that all of the previous
simulation work on BChE was with aglycosylated BChE, whereas this study is the first to
include glycosylated simulations of BChE.
Glycans are branched, flexible chains of carbohydrates that explore an ensemble of confor-
mations at equilibrium conditions. This complicates the structural characterization of glycans
using laboratory experiments. Conversely, atomistic MD simulations are well suited for glycan
characterization since their high±resolution atomic trajectories are easily analyzed to obtain
structural information. The main limitation of atomistic MD simulations are their restricted
length± and time±scales. Fortunately, improvements in computational power and efficiency
continues to progress, enabling an ever±improving characterizations of glycoprotein ensembles.
Materials and methods
The overall process to simulate BChE glycoforms is summarized in Fig 1. The sections below
describe the process components in detail. All molecular figures were generated using VMD
[16] and its built±in STRIDE secondary structure function [17] for protein representation.
Cavity volumes were generated with VOIDOO [18] using a grid spacing of 0.3 Å and a probe
radius of 1.4 Å, emulating a water probe.
BChE homology modeling
The atomic coordinates of recombinant BChE (rBChE) have been determined using X±ray
crystallography (PDB code 1P0I) [19]. However, this rBChE has mutations N17Q, N455Q,
Molecular dynamics of butyrylcholinesterase
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N481Q and N486Q, which deactivate four of the nine glycosylation sites. Additionally, only
residues 1±529 out of the 574 total were expressed. These modifications were made to reduce
the number of flexible residues that inhibit the crystallization process. To transform rBChE to
wild±type BChE, we used Modeller 9.16 [20] to revert the mutated residues and to reintroduce
the removed residues.
Residues 530±574 of BChE comprise the tetramerization domain, which is a long flexible
α±helix. AChE is homologically similar to BChE, and has also been studied using X±ray crys-
tallography (PDB code 4BDT) [21]. Performing sequence alignment with blastp [22], we used
4BDT as a template for modelling residues 530±557 of BChE. Similarly, segments of the AChE
tetramerization domain complexed with a left±handed polyproline helix have been crystallized
(PDB code 1VZJ) [23], and were used as an input for modelling BChE residues 534±567. Resi-
dues 568±574 do not have an experimentally crystallized structure and were simply modelled
initially as an α±helix. All inputs were simultaneously used to generate our BChE homology
model. A subsequent 20 ns simulation showed residues 568±574 degenerate to random coil.
These 7 residues are in fact intrinsically disordered, as tested with SPOT±Disorder [24]. The
results of our homology model and subsequent 20 ns simulation are shown in Fig 2.
Force fields
All simulations were performed using the GROMACS 5.1 simulation suite [25±27]. Protein
atoms were modeled using the Amber ff14SB force field [28], glycan atoms were modeled using
the GLYCAM06-j force field [29], and water atoms were modeled using the SPC/E force field
[30]. Since the GLYCAM06 force field has not been incorporated into GROMACS yet, Amber
topologies were first created using AmberTools16's LeaP [31], and then exported to GRO-
MACS topologies using a modified version of ACPYPE [32]. We caution the reader that the
published ACPYPE is designed to export the base AMBER force fields, which use uniform scal-
ing constants for nonbonded 1±4 interactions and non±negative dihedral force constants. The
Fig 1. Glycoprotein simulation workflow. Flowchart describing the overall procedure used to simulate
glycoproteins.
https://doi.org/10.1371/journal.pone.0187994.g001
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GLYCAM06-j force field uses variable scaling constants for 1±4 interactions and contains some
negative dihedral force constants. Consequently, the published ACPYPE will not properly con-
vert GLYCAM06-j. We modified ACPYPE such that negative dihedral force constants were
allowed, and every nonbonded 1±4 interaction was treated separately using the GROMACS
[nb_pairs] topology directive. S1 Fig shows the ability of our modified ACPYPE (to be pub-
lished) versus the published ACPYPE to reproduce a representative dihedral distribution of N±
acetylglucosamine from the GLYCAM06-j force field. Our modified version of ACPYPE is pub-
licly available in the GitHub repository https://github.com/austenb28/acpype_fix.
Virtual glycan attachment
All glycans were virtually attached using the glycoprotein builder of the GLYCAM web portal
[33]. Amber topologies were generated and converted to GROMACS topologies using the
methodology described above. Once the GROMACS topologies were generated, the attached
glycans were sequentially energy minimized in vacuo along the N±glycosidic and ωp bonds
(see S2 Fig), in order to relax the system and remove steric clashes for subsequent atomistic
MD simulations. The energy minimization process was coded in C++ using the GROMACS
environment, and the two rotatable bonds were each fully rotated at ten degree increments,
yielding 362 energy calculations per glycan. Only glycans that were previously minimized in
the sequential process were included in the energy calculations.
Table 1 details the BChE glycoforms that were simulated, while Fig 3 shows the CFG car-
toon representations of the glycans (i.e. NaNa and ANa) present in our simulations. The
human glycosylation profile of BChE was taken from the most predominant forms of reference
[34]. NaNa represents complex, biantennary human glycans, while ANa represents complex,
biantennary α 1,3±arm monosialylated human glycans. The glycan 241 (±) glycoform differs
from the human glycoform in that it is aglycosylated at site ASN241. A third simulation was
conducted that is identical to the human glycoform, but whose starting structure was taken
from the final coordinates of the glycan 241 (±) simulation. This simulation will be specified
separately as glycan 241 (+). As done above, the newly attached glycan 241 was minimized
prior to MD simulation.
General simulation setup
BChE histidine protonation states were determined using Reduce [36]. All non±water bonds
were constrained using LINCS [37], while water bonds and angles were constrained using the
Fig 2. Inputs and results of homology modelling of BChE. Homology model performed using Modeller 9.16 [20].
AChE and BChE are homologically similar, but their residues indices do not map one to one. Only AChE residues within
the tetramerization domain (BChE residues 530–574, AChE residues 540–584) were used as model inputs. The active
site SER198 is shown in purple, with the reader oriented directly above the gorge of the active site. The N terminus is at the
right, and the C terminus at the left in all images. Green glow indicates residues used as inputs in the model.
https://doi.org/10.1371/journal.pone.0187994.g002
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analytical SETTLE method [38]. Two initial model systems were createdÐone where the gly-
can 241 was present (i.e. human) and one where glycan 241 was absent (i.e. glycan 241 (±)).
The periodic, cubic simulation boxes for the human and glycan 241 (±) glycoforms had initial
dimensions of 16.1 × 16.1 × 16.1 nm3 and 15.9 × 15.9 × 15.9 nm3, respectively. The boxes were
constructed such that the minimium distance between each BChE glycoform to the periodic
boundary is 1.2 nm. Both BChE production simulations were performed for 100 ns in NPT
with data collected every 0.1 ns. Each production run was preceded by an energy minimization
in vacuum, solvation, solvated energy minimization, a 100 ps NVT equilibration, and subse-
quently 100 ps NPT equilibration. Both energy minimizations were terminated using a maxi-
mum force tolerance of 1000 kJ mol-1nm-1. In the solvation step, both systems were first
neutralized with the addition of Na+ or Cl- ions, and then concentrated to 155 mM NaCl. The
Velocity±rescale thermostat [39] was used with a reference temperature of 310 K, using a time
constant of 0.1 ps. Solvent molecules were thermostatted separately from the glycan and
Table 1. Simulated BChE glycoforms and their corresponding glycan distribution.
Glycan site Glycan 241 (–) Human and Glycan 241 (+)
N17 ANa ANa
N57 NaNa NaNa
N106 ANa ANa
N241 – NaNa
N256 ANa ANa
N341 NaNa NaNa
N455 NaNa NaNa
N481 NaNa NaNa
N486 NaNa NaNa
Proglycan nomenclature from www.proglycan.com. The ‘–’ symbol indicates the absence of a glycan. Note
that A = A4 and Na = Na6–4. Human and glycan 241 (+) simulations differ by their starting conformations.
https://doi.org/10.1371/journal.pone.0187994.t001
Fig 3. Simulated glycans. CFG cartoon representations of the proglycan abbreviations created with
GlycanBuilder [35]. Blue squares are N–acetylglucosamine, green circles are mannose, yellow circles are
galactose, and magenta diamonds are N-Acetylneuraminic acid. Linkages and anomeric centers are labeled.
https://doi.org/10.1371/journal.pone.0187994.g003
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protein residues. The isotropic Parrinello±Rahman barostat [40] was used with a reference
pressure of 1 bar, using a time constant of 2 ps and isothermal compressibility of 4.5 × 10−5
bar−1. Temperature, pressure, and NaCl concentration were selected to emulate human body
conditions. Harmonic position restraints were applied to the protein atoms during the NVT
and NPT equilibrations to ensure the equilibration process did not disrupt the natural protein
fold. All nonbonded interactions employed a short±range cutoff of 1 nm, with vertically shifted
potentials such that the potential at the cutoff range is zero. The Particle±Mesh Ewald method
[41] with cubic interpolation was used to model long±range electrostatic interactions. Disper-
sion correction was applied to both energy and pressure.
Results and discussion
BChE contains nine sites that can be glycosylated, as shown in Table 1. The attached glycans
for both glycoforms in their initial and final conformations are shown in Fig 4. Note that the
starting protein conformation for glycan 241 (±) simulation is the same as that shown in
Fig 4. Initial and final conformations. Initial (top) and final (bottom) conformations of the simulated human
(left) and glycan 241 (–) (right) glycoforms. Images are oriented such that the reader is viewing directly into the
active site gorge. Glycans are labeled in the top left image by color. An asterisk denotes a monosialylated
glycan. The active site SER198 is colored in pink.
https://doi.org/10.1371/journal.pone.0187994.g004
Molecular dynamics of butyrylcholinesterase
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human at t = 0 ns, while the starting protein conformation of glycan 241 (+) simulation is
identical to glycan 241 (±) at t = 100 ns. Videos of their stabilized trajectories are provided
(see S1, S2 and S3 Movies). The coordinate and topology files for all simulations are included
in S1 File.
Protein backbone RMSD
Root±mean±square deviation (RMSD) of the backbone atoms of the core domain from the ini-
tial and final structures of the human and glycan 241 (±) are shown in Fig 5. The RMSD at
time ti = iΔt, where Δt is the time resolution of the data, was calculated according to Eq 1
RMSDti 

1
N
XN
j1
Dd2ij
v
u
u
t ; 1
where N is the number of backbone atoms and Δdij is the deviation of atom j at time ti from a
reference position. RMSD was calculated post removal of translational and rotational displace-
ment of the protein's core domain residues 5±529 with the GROMACS ªgmx rmsº module.
Residues 1±4 and 530±574 were not included in the RMSD analysis since these residues consti-
tute the flexible regions of the protein, and contribute a significant skew in the backbone
RMSD values. The BChE glycoforms' core backbone RMSD values were below two angstroms,
confirming that the folded state was preserved throughout the simulation. We note that both
the initial and final frame RMSDs generally display trending, indicating that our conforma-
tional sampling of BChE's core backbone residues has not yet fully equilibrated. This is reason-
able, as protein folding is known to take place on the order of μs to s [42]. RMSD from the
initial conformation reveals that the structure of the human glycoform's core domain is signifi-
cantly closer to its initial conformation than glycan 241 (±) from approximately 30 ns to 90 ns.
RMSD from the final conformation shows that the final conformation of both glycoforms is
generally equally deviant from the rest of its respective simulation, except for the glycan 241
(±) glycoform at around 60 ns, where we see a 0.2 Å spike in the RMSD. Interestingly, this
spike is significantly less pronounced in the RMSD from the initial conformation, indicating
that RMSD from the final conformation is a more sensitive measure of fold deviations through
the simulation.
Conformational dihedral angle analysis
The dynamics of proteins and glycans can be analyzed through conformational dihedral
angles. For both, protein and glycans, there are three dihedral angles of interest, termed
Fig 5. Core backbone RMSD. Core backbone residues (5–529) atomic RMSD over 100 ns from the initial
conformation (left) and the final conformation (right) for the human and glycan 241 (-) simulations. of BChE.
https://doi.org/10.1371/journal.pone.0187994.g005
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ϕ, ψ and ω. Note that despite there being three dihedral angles identically named for protein
and glycan dihedrals, they are completely independent. Fig 6 depicts the locations of the glycan
and protein conformational dihedral angles.
We observe the median square angular displacement (MSAD), mean angular displacement
(MAD) and angular autocorrelation function (AACF) for all conformational dihedral angles
in our simulations. The MSAD for a time lag τi = iΔt is given by Eq 2
MSADti  medianl2Y;k2Ti
Xki 1
jk
Dyjl
 !2" #
; 2
where l denotes the lth conformational dihedral angle in the set of conformational dihedral
angles Θ, and Δθjl denotes the signed angular displacement of the lth conformational dihedral
angle from time tj to time tj + Δt. Ti is the set of usable time indices, which is simply all time
indices included in simulation time t = 0 to t = T − τi, where T is the total simulation time. The
median was selected as a measure of central tendency as opposed to the arithmetic mean, since
squared angular displacement follows a χ2 distribution, as angular displacement is Gaussian.
This expression is valid as long as |Δθjl|  180Ê for all j, l, which is consistent with our time res-
olution Δt.
The mean angular displacement (MAD) at a time lag τi is given by Eq 3
MADti 
1
NyNt   i
XNy
l1
XNt i
k1
Xki 1
jk
Dyjl; 3
where Nθ is the number of conformational dihedral angles and Nt is the total number of time
indices. The angular autocorrelation function (AACF) at time lag τi was calculated according
to Eq 4 [43]
AACFti  medianl2Y;k2Ti
cos
Xki 1
jk
Dyjl
 !" #
: 4
This AACF is the normalized autocorrelation function of the two vectors formed by projecting
the two dihedral planes onto the orthogonal plane. Fig 7 shows the MSAD, MAD and AACF
for the ϕ dihedral angles of the glycans in the human and glycan 241 (±) glycoforms. We see
Fig 6. Glycan and protein conformational dihedral angles. Glycan conformational dihedral angles ϕg,ψg, andωg of
α1-6 dimannose (left) and protein conformational dihedral angles ϕp,ψp, andωp of dialanine (right). Glycan linkages only
contain anωg when the linkage occurs on the terminal carbon; otherwise, the linkage only contains ϕg andψg.
https://doi.org/10.1371/journal.pone.0187994.g006
Molecular dynamics of butyrylcholinesterase
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that there is not much difference between the glycan conformational dihedral angles in terms
of MSAD, MAD, or AACF. The MSAD has a slope that is less than unity on a log±log plot,
indicating sub±diffusive behavior. The AACF remains near unity and slowly decreases, indi-
cating highly constrained dihedral motion. Comparing the MSAD, MAD and AACF of glycan
conformational dihedral angles to protein conformational dihedral angles, the protein dihedral
angles have a much flatter MSAD, indicating a greater degree of sub±diffusive behavior. The
MAD appears to become unstable at around τ = 2 ns for both the protein and glycan confor-
mational dihedral angles, but the behavior of the MAD instability between protein and glycan
is clearly different. The AACF is approximated well by a power law decay during τ = 0±2 ns,
which is consistent with previously reported power law autocorrelations in proteins [44, 45].
The AACF is better approximated by a linear function on the range of τ = 20±60 ns, indicating
that our correlations have not equilibrated on this timescale. The AACF is a full order of mag-
nitude closer to unity for the protein dihedral angles (1 −O(10−4) versus 1 −O(10−3)), indicat-
ing a higher degree of entrapment. This is expected as proteins are generally less flexible than
glycans. We note that for a truly entrapped dihedral, MSAD would eventually level out, MAD
would have a longer stability window, and AACF would approach a limiting value. This indi-
cates that longer simulation timescales are required to reach equilibrium. Still, our simulations
are long enough to provide dynamic insight on the 0.1 to 2 ns timescale.
We are able to extract diffusivity information from the MSAD using the equation for one±
dimensional anomalous diffusion given by Eq 5 [46]
MSAD  2Data; 5
where α is the anomalous diffusion exponent (α = 1 is diffusive, α< 1 is sub±diffusive, and
Fig 7. Dynamics of conformational dihedral angle ϕg. MSAD (left column), MAD (middle column) and
AACF (right column) of the ϕg (top row) and ϕp (bottom row) of the human and glycan 241 (–) BChE glycoform.
MSAD is displayed in log–log plots, while MAD and AACF are displayed in semi–log plots. The first and third
quartiles of the MSAD are shown in colored dashed lines, and a representative diffusive line is shown in a
black dashed line. A power law fit from τ = 0–2 ns of the AACF is shown in a dashed line, and a linear fit from
τ = 20–60 ns is also shown in a dashed line.
https://doi.org/10.1371/journal.pone.0187994.g007
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α> 1 is super±diffusive) and Dα is the prefactor (which for α = 1 becomes the diffusion coeffi-
cient). Fig 8 shows the combined MSAD for three representative glycans (see S3 Fig for the
complete plot). The glycan MSAD has roughly an order of magnitude spread for both glyco-
forms. The anomalous diffusion parameters for glycan conformational dihedral angles com-
bined and categorized by glycan are shown in Table 2. We note that the glycan 241 (±) glycan
has higher α and Dα for the following 6 of its 8 glycans: 17, 57, 106, 455, 481 and 486. The
reduced crowding resulting from the absence of glycan 241 is likely the cause of the increased
mobility of these glycans.
Fig 8. Representative glycan MSAD. MSAD of three representative glycans combining all ϕ,ψ andω
conformational dihedral angles in the Human and Glycan (–) glycoforms. Glycan 455 represents a lower
bound, 57 represents a higher bound, and 17 represent a central glycan. The asterisk on Glycan 17 indicates
a monosialilated glycan.
https://doi.org/10.1371/journal.pone.0187994.g008
Table 2. Anomalous diffusion parameters α and Dα for all glycan conformational dihedral angles categorized by glycan.
Glycoform: Human Glycan 241 (–)
Glycan α Dα (deg.2/ nsα) α Dα (deg.2/ nsα)
17* 0.39 3.22 0.35 5.40
57 0.40 16.71 0.42 17.05
106* 0.15 1.72 0.47 2.48
241 0.32 4.88 – –
256* 0.31 7.46 0.27 7.75
341 0.27 1.24 0.30 1.19
455 0.27 1.03 0.28 1.71
481 0.18 6.53 0.39 6.20
486 0.26 4.74 0.58 8.82
*monosialylated glycan
https://doi.org/10.1371/journal.pone.0187994.t002
Molecular dynamics of butyrylcholinesterase
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The parameters extracted from the glycan and protein MSAD are shown in Table 3. For
both glycoforms, ωg has greater α and Dα than both ϕg and ψg, which is to be expected since ωg
is always adjacent to two other fully rotatable bond, increasing its relative rotational freedom.
The glycan conformational dihedral angle α and Dα are significantly greater than the protein
conformational dihedral angles, consistent with glycans being more flexible than proteins. The
α and Dα for the protein dihedral angles are consistently higher for the human glycoform than
the glycan 241 (±) glycoform. This may be attributed to a reduction in mobility of the tetra-
merization domain for the glycan 241 (±) glycoform. This trend is directly related to the glycan
conformational mobility, as the glycan 241 (±) has consistently higher α and Dα for the glycan
conformational dihedral angles.
BChE active site
The active site conformation of BChE was affected by the presence or absence of glycan 241.
Fig 9 depicts the starting and ending conformations of the active site gorge for representative
simulated BChE glycoforms. The initial and final cavity volumes of the gorge are provided in
S1 Table. The accessibility of the gorge was found to be directly related to the center of mass
distance between residues ASP70 and combined residues THR284 and PRO285, displayed in Fig
10. The gorge remains accessible throughout the simulation for the human glycoform. How-
ever, the glycan 241 (±) glycoform's gorge becomes inaccessible at 65 ns, when the distance for
the glycan 241 (±) glycoform becomes and remains around 0.5 nm. The active site closure
event occurs directly proceeding the RMSD spike at 60 ns, exhibited in Fig 5, right. The
human glycoform simulation did not exhibit any closure events through its trajectory. In
order to affirm the correlation between the active site closure and the presence of glycan 241,
an additional simulation was performed on the fully glycosylated form whose initial coordi-
nates were taken from the glycan 241 (±) at 100 ns (i.e. glycan 241 (+)). From Figs 9 and 10, we
see the gorge quickly reopens upon reintroduction of glycan 241. We note that the distance in
Fig 10 for the glycan 241 (+) does not reach the value of the human glycoform simulation. Fig
9 top right shows the α 1,3±arm galactose and N±-Acetylneuraminic acid in close proximity to
gorge±lining residues. This interaction is not present in the glycan 241 (+) simulation, likely
due to limited simulation time. Collectively, this information suggests that glycan 241 is an
important factor in the activity of BChE glycoforms.
BChE tetramerization domain
The behavior of the tetramerization domain was highly dependent on the simulated BChE gly-
coform. Fig 11 shows secondary structure overlays of the simulated BChE glycoforms,
Table 3. Anomalous diffusion parameters α and Dα for all glycan and protein conformational dihedral angles categorized by conformational dihe-
dral angle.
Glycoform: Human Glycan 241 (−)
Angle α Dα (deg.2/ nsα) α Dα (deg.2/ nsα)
ϕg 0.27 3.60 0.37 4.47
ψg 0.28 3.21 0.38 4.28
ωg 0.33 4.34 0.40 5.87
ϕp 0.14 1.69 0.12 1.48
ψp 0.14 1.71 0.12 1.50
ωp 0.14 1.68 0.12 1.52
Glycan conformational dihedral angles are denoted by the g subscript and protein are denoted by the p subscript.
https://doi.org/10.1371/journal.pone.0187994.t003
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omitting the glycans. The active site SER198 is occluded in the glycan 241 (±) simulation, indi-
cating that the glycan attached to ASN241 is critical to BChE activity.
The shape of the BChE tetramerization domain may be characterized by the radius of gyra-
tion Rg along its first principle component. The Rg of the BChE tetramerization domain for the
human and glycan 241 (±) glycoforms are displayed in Fig 12, calculated using the GROMACS
ªgmx gyrateº module. This statistic describes how wide the tetramerization domain is per-
pendicular to its longest axis. The glycan 241 (±) glycoform has a distinctly wider Rg distribu-
tion after 100 ns of simulation than the human glycoform, consistent with the visible bend in
the tetramerization domain, exhibited in Fig 4, bottom right. From Fig 12, the tetramerization
domain of the glycan 241 (±) glycoform becomes locked into its bent conformation around 28
ns, while the human glycoform remains generally elongated through the entire simulation.
The glycan 241 (+) simulation also retains a bent tetramerization domain, possibly trapped
in a local minimum energy structure (see S1, S2 and S3 Movies). We hypothesize that an
Fig 9. Active site gorge. Active site cavity images of the simulated BChE glycoforms. The human cavity at
t = 0 ns (top left) is representative of the glycan 241 (–) cavity at t = 0 ns. The glycan 241 (–) cavity at t = 100 ns
(bottom left) is representative of the glycan 241 (+) cavity at t = 100 ns. Cavities were generated using
VOIDOO [18]. The cavity surface shown represents the surface accessible to the center of a probe of radius
1.4 Å. Protein residues lining the entrance are opaque, with select residues in licorice representation. ASP70,
THR284 and PRO285 are enlarged, as their grouped center of mass distance distance is used to represent
gorge accessibility. Glycan 241 is the only glycan shown, and is colored according to Fig 3.
https://doi.org/10.1371/journal.pone.0187994.g009
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Fig 10. Active site residue distance. Center of mass distance between ASP70 and combined residues
THR284 and PRO285. These residues are located at the top of the active site gorge, and characterize the
opening and closing of the gorge.
https://doi.org/10.1371/journal.pone.0187994.g010
Fig 11. Secondary structure overlays. 100 ns, 1000 frame secondary structure overlays of human (left) and glycan 241 (–) (right) BChE
glycoforms. α–helices are colored in gray, β–sheets in red, 310–helices in orange, coil in white and turn in cyan. The active site SER198 is colored in
green.
https://doi.org/10.1371/journal.pone.0187994.g011
Fig 12. Tetramerization domain radius of gyration. Radius of gyration along the longest principal
component of the BChE tetramerization domain, residues 530–574.
https://doi.org/10.1371/journal.pone.0187994.g012
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extension of the glycan 241 (+) simulation would result in a conformation closer to that of the
human simulation.
Conclusion
The human BChE glycoform was simulated with and without glycan 241 present. Fully glyco-
sylated human BChE was generally more structurally stable, exhibiting lower RMSD and lower
mobility in glycan conformational dihedral angles. From the MAD and AACF data we found
that 100 ns simulations were long enough to provide dynamical insight on conformational
dihedral angles of glycans and protein for τ = 0±2 ns. We note that our conformational dihe-
dral angle data indicates that longer simulation times are required for an accurate analysis of
the equilibrium conformational ensemble of BChE, which is especially true for the highly flexi-
ble glycans. Nevertheless, useful structural information is obtained from the timescale simu-
lated within this work. Our simulations indicate that the activity of the BChE monomer is
heavily dependent on the presence of glycan 241. This dependency was exhibited by the dis-
tance measurement of ASP70 with combined residues THR284 and PRO285 and correlated to
the RMSD from the final conformation. The closed conformation of the glycan 241 (±) glyco-
form was resimulated with glycan 241 reintroduced, and the active site partially reopened. The
tetramerization domain remained bent in the glycan 241 (+) simulation. If the tetramerization
domain in the glycan 241 (+) simulation were elongated as it is in the tetramer, we hypothesize
that the active site will eventually fully open.
Supporting information
S1 Table. Initial and final cavity volumes computed by VOIDOO.
(PDF)
S1 Fig. Representative dihedral probability distribution. Representative dihedral angle
probability distribution for GlcNac using Amber (blue), Gromacs with the original ACPYPE
(red), and Gromacs with a modified version of ACPYPE that correctly transfers 1±4 scaling
parameters (green).
(TIF)
S2 Fig. Rotable bonds for glycan energy minimization. N±glycosidic and ωp bonds for which
the glycans are rotated along for the initial energy minimization procedure.
(TIF)
S3 Fig. Glycan MSAD. MSAD of all glycans combining all ϕg, ψg, and ωg conformational dihe-
dral angles in the Human and Glycan (±) glycoforms. The color scheme corresponds directly
to the glycans represented in Fig 4.
(TIF)
S1 Movie. Video of the 100 ns human BChE simulation. Solvent omitted and glycoform sta-
bilized by core residues 5±529.
(MP4)
S2 Movie. Video of the 100 ns glycan 241 (±) BChE simulation. Solvent omitted and glyco-
form stabilized by core residues 5±529.
(MP4)
S3 Movie. Video of the 100 ns glycan 241 (+) BChE simulation. Solvent omitted and glyco-
form stabilized by core residues 5±529.
(MP4)
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S1 File. Simulation files. Starting coordinate and topology files for the simulations presented
in this work in GROMACS format. These files are post±glycan energy minimization.
(ZIP)
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